

## FOR IMMEDIATE RELEASE

---

For more information, contact:

**Kevin M. Smith**  
President & CEO  
CID4  
[kevin.smith@cid4.com](mailto:kevin.smith@cid4.com)  
(720) 859-4043

### **CID4 Announces Due Date for Spring 2014 New Project Consideration**

*The Colorado Institute for Drug, Device and Diagnostic Development (CID4) is seeking its next Portfolio Company, and has set Monday March 24th as the due date for submitting material to CID4.com for consideration.*

**Aurora, CO March 5, 2014** – The Colorado Institute for Drug, Device and Diagnostic Development (CID4), a 501(c)(3) not-for-profit entity focused on advancing the Colorado life science ecosystem through company creation and job growth, is seeking its next Portfolio Company. Monday March 24th has been set as the deadline for submitting material to for consideration.

CID4 maintains an online database for business plans to be submitted on a rolling basis. The database is more than just a location for project submissions for CID4 review; it is a powerful tool that enables industry partners and investors from all over world to reach into the technology-rich Colorado life science ecosystem. Providing an efficient, single point of entry, the database has been well received by both investors and Colorado entrepreneurs. Business plans uploaded to the CID4 database have been presented at numerous premiere partnering and investor conferences such as C21 BioVentures, BIO, and BioPartnering North America.

Those who submit their content by March 24th will be considered by CID4 management and its Technical and Business Advisory Committee (TBAC). A use-of-proceeds budget for up to \$200,000 should be included with your submission. For details about the project selection process and where to submit materials, visit [http://gust.com/organizations/cid4/group\\_profile\\_submit\\_a\\_startup](http://gust.com/organizations/cid4/group_profile_submit_a_startup).

“The Colorado life science industry continues to drive innovations resulting in lower healthcare costs and improved patient outcomes,” said Kevin M. Smith, President and CEO of CID4. “We are proud to be part of this infrastructure and look forward to seeing more new technologies during this evaluation cycle.”

CID4 has invested over \$2.5 million in its eight Portfolio Companies, which have in turn raised over \$25 million in follow-on investment and grant or contract funding and have created approximately 85 new, direct jobs. While working with its Portfolio investments, CID4 has continued to strengthen its network with the sources of technology and funding within the State. CID4 is delivering on its mission of Economic Development through Innovation Advancement.

**FOR IMMEDIATE RELEASE**

---

**About the Colorado Institute for Drug, Device and Diagnostic Development**

Founded in 2009, the Colorado Institute for Drug, Device and Diagnostic Development (CID4) is a 501(c)(3) not-for-profit charitable organization whose mission is to advance the Colorado bioscience ecosystem through company creation and job growth. Active business management and capital work in tandem to help bridge the gap between discovery and product development. CID4 works to identify, fund and actively manage emerging life science technologies. This aim is achieved via an ongoing technology solicitation process augmented by additional deal flow sourcing through networked relationships. Active due diligence is provided by CID4 management in consultation with members of the CID4 Technical and Business Advisory Committee. For more information visit <http://CID4.com>.

###